Shareen Doak

List of Publications by Year
in descending order

121 papers	5,987 citations	109321 35 h-index	76900 74 g-index
124 all docs	124 docs citations	124 times ranked	8543 citing authors

#	Article	IF	Citations
1	Deducing the cellular mechanisms associated with the potential genotoxic impact of gold and silver engineered nanoparticles upon different lung epithelial cell lines inÂvitro. Nanotoxicology, 2022, , 1-21.	3.0	3
2	The Road to Achieving the European Commission's Chemicals Strategy for Nanomaterial Sustainabilityâ€"A PATROLS Perspective on New Approach Methodologies. Small, 2022, 18, e2200231.	10.0	9
3	The influence of exposure approaches to <i>inÂvitro</i> lung epithelial barrier models to assess engineered nanomaterial hazard. Nanotoxicology, 2022, 16, 114-134.	3.0	6
4	The application of existing genotoxicity methodologies for grouping of nanomaterials: towards an integrated approach to testing and assessment. Particle and Fibre Toxicology, 2022, 19, 32.	6.2	5
5	Common Considerations for Genotoxicity Assessment of Nanomaterials. Frontiers in Toxicology, 2022, 4, .	3.1	8
6	Industrial-relevant TiO2 types do not promote cytotoxicity in the A549 or TK6 cell lines regardless of cell specific interaction. Toxicology in Vitro, 2022, 83, 105415.	2.4	2
7	In Vitro Primaryâ€Indirect Genotoxicity in Bronchial Epithelial Cells Promoted by Industrially Relevant Fewâ€Layer Graphene. Small, 2021, 17, e2002551.	10.0	21
8	Multiple-endpoint in vitro carcinogenicity test in human cell line TK6 distinguishes carcinogens from non-carcinogens and highlights mechanisms of action. Archives of Toxicology, 2021, 95, 321-336.	4.2	6
9	Few-layer graphene induces both primary and secondary genotoxicity in epithelial barrier models in vitro. Journal of Nanobiotechnology, 2021, 19, 24.	9.1	21
10	In Vitro Threeâ€Dimensional Liver Models for Nanomaterial DNA Damage Assessment. Small, 2021, 17, e2006055.	10.0	17
11	Simulating Nanomaterial Transformation in Cascaded Biological Compartments to Enhance the Physiological Relevance of In Vitro Dosing Regimes: Optional or Required?. Small, 2021, 17, e2004630.	10.0	11
12	Advanced In Vitro Models for Replacement of Animal Experiments. Small, 2021, 17, e2101474.	10.0	6
13	Understanding the impact of more realistic low-dose, prolonged engineered nanomaterial exposure on genotoxicity using 3D models of the human liver. Journal of Nanobiotechnology, 2021, 19, 193.	9.1	15
14	<i>In vitro</i> and integrated <i>in vivo</i> strategies to reduce animal use in genotoxicity testing. Mutagenesis, 2021, 36, 389-400.	2.6	7
15	Inter-laboratory variability of A549 epithelial cells grown under submerged and air-liquid interface conditions. Toxicology in Vitro, 2021, 75, 105178.	2.4	26
16	Comprehensive framework for human health risk assessment of nanopesticides. Nature Nanotechnology, 2021, 16, 955-964.	31.5	48
17	Overview of Nanotoxicology in Humans and the Environment; Developments, Challenges and Impacts. Molecular and Integrative Toxicology, 2021, , 1-40.	0.5	0
18	Detection of urethane-induced genotoxicity <i>in vitro</i> using metabolically competent human 2D and 3D spheroid culture models. Mutagenesis, 2020, 35, 445-452.	2.6	3

#	Article	IF	Citations
19	The effect of chronic dosing and p53 status on the genotoxicity of pro-oxidant chemicals <i>in vitro</i>. Mutagenesis, 2020, 35, 479-489.	2.6	1
20	Translating Scientific Advances in the AOP Framework to Decision Making for Nanomaterials. Nanomaterials, 2020, 10, 1229.	4.1	29
21	Risk Governance of Emerging Technologies Demonstrated in Terms of its Applicability to Nanomaterials. Small, 2020, 16, e2003303.	10.0	28
22	An Alternative Perspective towards Reducing the Risk of Engineered Nanomaterials to Human Health. Small, 2020, 16, e2002002.	10.0	17
23	Dietary and lifestyle factors effect erythrocyte<i>PIG-A</i>mutant frequency in humans. Mutagenesis, 2020, 35, 405-413.	2.6	6
24	Adaptation of the <i>in vitro</i> micronucleus assay for genotoxicity testing using 3D liver models supporting longer-term exposure durations. Mutagenesis, 2020, 35, 319-330.	2.6	29
25	Comparison of passive-dosed and solvent spiked exposures of pro-carcinogen, benzo[a]pyrene, to human lymphoblastoid cell line, MCL-5. Toxicology in Vitro, 2020, 67, 104905.	2.4	8
26	Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure. Journal of Visualized Experiments, 2020, , .	0.3	14
27	Emerging Standards and Analytical Science for Nanoenabled Medical Products. Annual Review of Analytical Chemistry, 2020, 13, 431-452.	5.4	11
28	Nanomaterials and Innate Immunity: A Perspective of the Current Status in Nanosafety. Chemical Research in Toxicology, 2020, 33, 1061-1073.	3.3	34
29	Utilisation of the STEAP protein family in a diagnostic setting may provide a more comprehensive prognosis of prostate cancer. PLoS ONE, 2019, 14, e0220456.	2.5	28
30	Cellular Defense Mechanisms Following Nanomaterial Exposure: A Focus on Oxidative Stress and Cytotoxicity. Nanoscience and Technology, 2019, , 243-254.	1.5	2
31	In vitro detection of in vitro secondary mechanisms of genotoxicity induced by engineered nanomaterials. Particle and Fibre Toxicology, 2019, 16, 8.	6.2	40
32	Horizon scanning for novel and emerging in vitro mammalian cell mutagenicity test systems. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2019, 847, 403024.	1.7	3
33	STEAP2 Knockdown Reduces the Invasive Potential of Prostate Cancer Cells. Scientific Reports, 2018, 8, 6252.	3.3	33
34	A three-dimensional in vitro HepG2 cells liver spheroid model for genotoxicity studies. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2018, 825, 51-58.	1.7	68
35	Skin tissue engineering using 3D bioprinting: An evolving research field. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2018, 71, 615-623.	1.0	136
36	Genotoxicity Assessment of Nanomaterials: Recommendations on Best Practices, Assays, and Methods. Toxicological Sciences, 2018, 164, 391-416.	3.1	71

#	Article	IF	Citations
37	A novel, integrated in vitro carcinogenicity test to identify genotoxic and non-genotoxic carcinogens using human lymphoblastoid cells. Archives of Toxicology, 2018, 92, 935-951.	4.2	25
38	Investigating FlowSightÂ® imaging flow cytometry as a platform to assess chemically induced micronuclei using human lymphoblastoid cells in vitro. Mutagenesis, 2018, 33, 283-289.	2.6	12
39	Considerations for the Human Health Implications of Nanotheranostics. , 2018, , 279-303.		3
40	Reprint of: A three-dimensional in vitro HepG2 cells liver spheroid model for genotoxicity studies. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2018, 834, 35-41.	1.7	9
41	Genotoxicity and Cancer. , 2017, , 423-445.		6
42	The role of intracellular trafficking of CdSe/ZnS QDs on their consequent toxicity profile. Journal of Nanobiotechnology, 2017, 15, 45.	9.1	31
43	Investigation of J-shaped dose-responses induced by exposure to the alkylating agent N -methyl- N -nitrosourea. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2017, 819, 38-46.	1.7	4
44	Choose your cell model wisely: The in vitro nanoneurotoxicity of differentially coated iron oxide nanoparticles for neural cell labeling. Acta Biomaterialia, 2017, 55, 204-213.	8.3	13
45	NanoGenotoxicology: present and the future. Mutagenesis, 2017, 32, 1-4.	2.6	32
46	Evaluation of the automated MicroFlowÂ® and Metaferâ„¢ platforms for high-throughput micronucleus scoring and dose response analysis in human lymphoblastoid TK6 cells. Archives of Toxicology, 2017, 91, 2689-2698.	4.2	17
47	Characterizing Nanoparticles in Biological Matrices: Tipping Points in Agglomeration State and Cellular Delivery <i>In Vitro</i>. ACS Nano, 2017, 11, 11986-12000.	14.6	33
48	Aligning nanotoxicology with the 3Rs: What is needed to realise the short, medium and long-term opportunities?. Regulatory Toxicology and Pharmacology, 2017, 91, 257-266.	2.7	36
49	Critical review of the current and future challenges associated with advanced<i>in vitro</i>systems towards the study of nanoparticle (secondary) genotoxicity. Mutagenesis, 2017, 32, 233-241.	2.6	75
50	Is Nickel Chloride really a Nonâ€Genotoxic Carcinogen?. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 10-15.	2.5	21
51	Coating of Quantum Dots strongly defines their effect on lysosomal health and autophagy. Acta Biomaterialia, 2017, 48, 195-205.	8.3	42
52	The 3Rs as a framework to support a 21st century approach for nanosafety assessment. Nano Today, 2017, 12, 10-13.	11.9	65
53	Emerging metrology for high-throughput nanomaterial genotoxicology. Mutagenesis, 2017, 32, 215-232.	2.6	43
54	Factors affecting the<i>in vitro</i>micronucleus assay for evaluation of nanomaterials. Mutagenesis, 2017, 32, 151-159.	2.6	31

#	Article	IF	Citations
55	Tissue-Engineered Solutions in Plastic and Reconstructive Surgery: Principles and Practice. Frontiers in Surgery, 2017, 4, 4.	1.4	37
56	Exposure to Engineered Nanomaterials: Impact on DNA Repair Pathways. International Journal of Molecular Sciences, 2017, 18, 1515.	4.1	31
57	A Crosstalk Between <i>K ras</i> (Kirsten Rat Sarcoma Viral Oncogene Homologue) and Adherence Molecular Complex Leads to Disassociation of Cellsâ€"A Possible Contribution Towards Metastasis in Colorectal Cancer. Journal of Cellular Biochemistry, 2016, 117, 2340-2345.	2.6	1
58	Opinion of the Scientific Committee on consumer safety (SCCS) - Opinion on the use of 2,2â€²-methylene-bis-(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol) (nano) â€" S79 â€" In cosmetic products. Regulatory Toxicology and Pharmacology, 2016, 76, 215-216.	2.7	4
59	A comparison of the genotoxicity of benzo[a]pyrene in four cell lines with differing metabolic capacity. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2016, 808, 8-19.	1.7	32
60	Empirical analysis of BMD metrics in genetic toxicology part I:<i>in vitro</i>analyses to provide robust potency rankings and support MOA determinations. Mutagenesis, 2016, 31, 255-263.	2.6	68
61	The clastogenicity of 4NQO is cell-type dependent and linked to cytotoxicity, length of exposure and p53 proficiency. Mutagenesis, 2016, 31, 171-180.	2.6	16
62	Adipose regeneration and implications for breast reconstruction: update and the future. Gland Surgery, 2016, 5, 227-41.	1.1	30
63	Genetic toxicity assessment of engineered nanoparticles using a 3D in vitro skin model (EpiDermâ„¢). Particle and Fibre Toxicology, 2015, 13, 50.	6.2	51
64	Acute Dosing and p53-Deficiency Promote Cellular Sensitivity to DNA Methylating Agents. Toxicological Sciences, 2015, 144, 357-365.	3.1	9
65	Cell Type-Dependent Changes in CdSe/ZnS Quantum Dot Uptake and Toxic Endpoints. Toxicological Sciences, 2015, 144, 246-258.	3.1	53
66	New approaches to advance the use of genetic toxicology analyses for human health risk assessment. Toxicology Research, 2015, 4, 667-676.	2.1	34
67	Increased expression of ARF GTPases in prostate cancer tissue. SpringerPlus, 2015, 4, 342.	1.2	11
68	Genotoxic capacity of Cd/Se semiconductor quantum dots with differing surface chemistries. Mutagenesis, 2015, 31, gev061.	2.6	21
69	Quantum dot induced cellular perturbations involving varying toxicity pathways. Toxicology Research, 2015, 4, 623-633.	2.1	13
70	A role for STEAP2 in prostate cancer progression. Clinical and Experimental Metastasis, 2014, 31, 909-920.	3.3	48
71	Automation and validation of micronucleus detection in the 3D EpiDermâ„¢ human reconstructed skin assay and correlation with 2D dose responses. Mutagenesis, 2014, 29, 165-175.	2.6	27
72	Unraveling the effects of siRNA carrier systems on cell physiology: a multiparametric approach demonstrated on dextran nanogels. Nanomedicine, 2014, 9, 61-76.	3.3	5

#	Article	IF	Citations
73	The effect of nanoparticle degradation on poly(methacrylic acid)-coated quantum dot toxicity: The importance of particle functionality assessment in toxicology. Acta Biomaterialia, 2014, 10, 732-741.	8.3	57
74	Chromosome Breakage Induced by the Genotoxic Agents Mitomycin C and Cytosine arabinoside is Concentration and p53 Dependent. Toxicological Sciences, 2014, 140, 94-102.	3.1	24
75	Recommendations, evaluation and validation of a semi-automated, fluorescent-based scoring protocol for micronucleus testing in human cells. Mutagenesis, 2014, 29, 155-164.	2.6	36
76	Genotoxins induce binucleation in L5178Y and TK6 cells. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2014, 770, 29-34.	1.7	11
77	Putative prognostic epithelial-to-mesenchymal transition biomarkers for aggressive prostate cancer. Experimental and Molecular Pathology, 2013, 95, 220-226.	2.1	29
78	Fluorescent non-porous silica nanoparticles for long-term cell monitoring: Cytotoxicity and particle functionality. Acta Biomaterialia, 2013, 9, 9183-9193.	8.3	40
79	Genotoxicity of nanomaterials: Refining strategies and tests for hazard identification. Environmental and Molecular Mutagenesis, 2013, 54, 229-239.	2.2	46
80	Influence of DNA Repair on Nonlinear Dose-Responses for Mutation. Toxicological Sciences, 2013, 132, 87-95.	3.1	65
81	Single-walled carbon nanotubes: differential genotoxic potential associated with physico-chemical properties. Nanotoxicology, 2013, 7, 144-156.	3.0	46
82	The jury is still out on the safety of silver nanoparticles. BMJ, The, 2013, 346, f227-f227.	6.0	2
83	The Role of Adhesion Molecules as Biomarkers for the Aggressive Prostate Cancer Phenotype. PLoS ONE, 2013, 8, e81666.	2.5	6
84	The In Vitro Micronucleus Assay and Kinetochore Staining: Methodology and Criteria for the Accurate Assessment of Genotoxicity and Cytotoxicity. Methods in Molecular Biology, 2013, 1044, 269-289.	0.9	13
85	Pro-oxidant Induced DNA Damage in Human Lymphoblastoid Cells: Homeostatic Mechanisms of Genotoxic Tolerance. Toxicological Sciences, 2012, 128, 387-397.	3.1	30
86	Modification of Schottky interface by the inclusion of DNA interlayer to create metal / organic / inorganic structures. , 2012, , .		2
87	In vitro genotoxicity testing strategy for nanomaterials and the adaptation of current OECD guidelines. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2012, 745, 104-111.	1.7	200
88	Preface. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2012, 745, 1-3.	1.7	3
89	Real-Time Reverse-Transcription Polymerase Chain Reaction: Technical Considerations for Gene Expression Analysis. Methods in Molecular Biology, 2012, 817, 251-270.	0.9	10
90	Genotoxicity and Cancer. , 2012, , 243-261.		6

#	Article	IF	Citations
91	Cytotoxic Effects of Gold Nanoparticles: A Multiparametric Study. ACS Nano, 2012, 6, 5767-5783.	14.6	239
92	The role of iron redox state in the genotoxicity of ultrafine superparamagnetic iron oxide nanoparticles. Biomaterials, 2012, 33, 163-170.	11.4	129
93	Quantum Dots for Multiplexed Detection and Characterisation of Prostate Cancer Cells Using a Scanning Near-Field Optical Microscope. PLoS ONE, 2012, 7, e31592.	2.5	16
94	Investigating Mechanisms for Non-linear Genotoxic Responses, and Analysing Their Effects in Binary Combination. Genes and Environment, 2012, 34, 179-185.	2.1	13
95	Dextran Coated Ultrafine Superparamagnetic Iron Oxide Nanoparticles: Compatibility with Common Fluorometric and Colorimetric Dyes. Analytical Chemistry, 2011, 83, 3778-3785.	6.5	55
96	STEM mode in the SEM: A practical tool for nanotoxicology. Nanotoxicology, 2011, 5, 215-227.	3.0	26
97	N-Methylpurine DNA Glycosylase Plays a Pivotal Role in the Threshold Response of Ethyl Methanesulfonateâ€“Induced Chromosome Damage. Toxicological Sciences, 2011, 119, 346-358.	3.1	39
98	Genotoxic thresholds, DNA repair, and susceptibility in human populations. Toxicology, 2010, 278, 305-310.	4.2	39
99	Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Reviews, 2010, 1, 5358.	3.7	861
100	Vinblastine and diethylstilboestrol tested in the in vitro mammalian cell micronucleus test (MNvit) at Swansea University UK in support of OECD draft Test Guideline 487. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2010, 702, 189-192.	1.7	10
101	NanoGenotoxicology: The DNA damaging potential of engineered nanomaterials. Biomaterials, 2009, 30, 3891-3914.	11.4	998
102	Non-linear doseâ€“response of DNA-reactive genotoxins: Recommendations for data analysis. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2009, 678, 95-100.	1.7	63
103	Confounding experimental considerations in nanogenotoxicology. Mutagenesis, 2009, 24, 285-293.	2.6	208
104	High-resolution imaging using a novel atomic force microscope and confocal laser scanning microscope hybrid instrument: essential sample preparation aspects. Histochemistry and Cell Biology, 2008, 130, 909-916.	1.7	34
105	No-observed effect levels are associated with up-regulation of MGMT following MMS exposure. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2008, 648, 9-14.	1.0	33
106	Aneuploidy in upper gastro-intestinal tract cancersâ€”A potential prognostic marker?. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2008, 651, 93-104.	1.7	15
107	Mechanistic Influences for Mutation Induction Curves after Exposure to DNA-Reactive Carcinogens. Cancer Research, 2007, 67, 3904-3911.	0.9	185
108	Identification of Early p53 Mutations in Clam Ileocystoplasties Using Restriction Site Mutation Assay. Urology, 2007, 70, 905-909.	1.0	8

#	Article	IF	Citations
109	Fluorescence imaging and investigations of directly labelled chromosomes using scanning near-field optical microscopy. Ultramicroscopy, 2007, 107, 308-312.	1.9	10
110	Comparative genomic hybridization (CGH) of augmentation cystoplasties. International Journal of Urology, 2007, 14, 539-544.	1.0	12
111	Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer. Cancer Genetics and Cytogenetics, 2007, 176, 161-165.	1.0	16
112	Do dose response thresholds exist for genotoxic alkylating agents?. Mutagenesis, 2005, 20, 389-398.	2.6	108
113	Fluorescence in situ hybridisation analysis of chromosomal aberrations in gastric tissue: the potential involvement of Helicobacter pylori. British Journal of Cancer, 2005, 92, 1759-1766.	6.4	28
114	Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett's oesophagusâ€"their association with aneuploidy and neoplastic progression. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2004, 547, 133-144.	1.0	40
115	Generation of locus-specific probes for interphase fluorescence in situ hybridisationâ€"application in Barrett's esophagus. Experimental and Molecular Pathology, 2004, 77, 26-33.	2.1	6
116	The bile acid deoxycholic acid (DCA) at neutral pH activates NF-ÂB and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis, 2003, 25, 317-323.	2.8	113
117	Early p53 mutations in nondysplastic Barrett's tissue detected by the restriction site mutation (RSM) methodology. British Journal of Cancer, 2003, 88, 1271-1276.	6.4	25
118	Characterisation of p53 status at the gene, chromosomal and protein levels in oesophageal adenocarcinoma. British Journal of Cancer, 2003, 89, 1729-1735.	6.4	36
119	Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus. Gut, 2003, 52, 623-628.	12.1	62
120	Analysis of the premalignant stages of Barrett's oesophagus through to adenocarcinoma by comparative genomic hybridization. European Journal of Gastroenterology and Hepatology, 2002, 14, 1179-1186.	1.6	26
121	Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. British Journal of Surgery, 2002, 89, 824-837.	0.3	108